Who actually funds Australian healthtech?
We mapped 131 investors sitting behind 288 ANZ healthtech companies. The names at the top of the table are not the ones you would guess.
Ask most people to name the biggest backers of Australian healthtech and you will hear the usual venture brands. Blackbird. AirTree. Square Peg. They are all active, and they all show up in the data. But none of them sits at the top.
We pulled together every investor we could find behind Australian healthtech companies since 2020. The result is a ladder of 131 investors behind 288 companies, with more than 450 individual backings between them. Ranked by how many healthtech companies each one has on its books, here is the head of the table:
1. Artesian Venture Partners (39) · VC
2. Medical Angels (32) · Angel network (portfolio funds: Archangel and Giant Leap)
3. UNSW Founders 10x (28) · Accelerator
4. Medical Research Future Fund (MRFF) (25) · Government
5. Startmate (21) · Accelerator
6. Blackbird Ventures (16) · VC
7. Breakthrough Victoria (13) · Government
8. Archangel Ventures (12) · VC
9. Antler (12) · Accelerator
10. Giant Leap Fund (11) · VC
The busiest backer is Artesian, an early-stage fund that invests at volume rather than picking one winner at a time. Below it, the pattern is the real story. An angel network, a university accelerator, a government fund and another accelerator all rank above the first household-name VC. Blackbird, the highest placed of the marquee brands, comes in sixth. AirTree sits twelfth. Square Peg, for all its profile, is well down the list on three healthtech companies.
Breadth is not the same as weight
One caveat matters before reading too much into that. This counts companies, not dollars. A fund that writes ten small cheques out-ranks a fund that writes one very large one, even where the second has put far more money to work. So the ladder measures breadth of activity, the number of bets, not the size of them.
That is exactly why the order looks the way it does. The names at the top are built for breadth. Accelerators run cohorts. Angel networks pool lots of small tickets. Government programs fund in rounds. Artesian's whole model is deliberately high volume. The marquee VCs do the opposite, fewer and larger and more concentrated, which is why they sit lower on a pure count even while writing some of the biggest cheques in the sector. Both things are true at once: the brand-name funds carry the dollars, and the programmatic backers carry the breadth.
Most investors are one and done
The shape of the curve is just as telling. Six in ten of these investors, 61 per cent, have backed exactly one healthtech company. The top ten names account for almost half of all the activity, and the top twenty for nearly two thirds. It is a steep power law: a small group of repeat backers doing most of the work, and a very long tail of investors who have dipped in once and not come back.
For founders that is worth knowing. If you are raising early, the people who do this repeatedly, the accelerators, the angel networks and the handful of genuinely active early-stage funds, are a far better use of your time than chasing the long tail who have made a single opportunistic bet.
“Government” is a top-five force
The detail that tends to surprise people offshore: public money is one of the largest backers in the sector. Eleven government vehicles appear in the data, behind 51 companies between them. The Medical Research Future Fund alone sits fourth overall, ahead of every brand-name VC. Add Breakthrough Victoria, the Industry Growth Program, the National Reconstruction Fund, LaunchVIC and a string of state health departments, and the public purse becomes a structural part of the early-stage stack in a way you do not see in the United States or the United Kingdom.
That is not a footnote. It shapes who gets funded, what gets funded, and how founders should think about where their first cheque comes from.
A note on the data
This is a curated set, built by hand from public announcements, not a complete census. It covers named investments from 2020 to 2026, and it counts companies rather than capital. Names have been cleaned and de-duplicated so the same company is not double counted across spellings. Read it as a map of who is active and how broadly, not a measure of how much.
This is the first cut. Over the next few pieces we will look at where the public money actually lands, where the offshore cheques are going, and which companies have pulled in the widest syndicates.
Want to see the full data set? Or need forensic-level analysis and reporting for a specific project? Clinical Advisors does exactly that. Reach out to terry@clinicaladvisors.com.au today.
